Status:
COMPLETED
Receptor Occupancy of ITI-007 Using Positron Emission Tomography (PET) in Patients With Stable Schizophrenia
Lead Sponsor:
Intra-Cellular Therapies, Inc.
Conditions:
Schizophrenia
Eligibility:
All Genders
18-60 years
Phase:
PHASE2
Brief Summary
The purpose of this study is to determine the relationship between ITI-007 dose, plasma levels and brain receptor occupancy in patients with stable schizophrenia.
Eligibility Criteria
Inclusion
- Patients with schizophrenia who are drug-free with regard to their antipsychotic medication
- In clinical remission and free from acute exacerbation of their psychosis
- In good health
Exclusion
- Clinically significant medical conditions considered inappropriate for trial participation
Key Trial Info
Start Date :
October 1 2014
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
September 1 2015
Estimated Enrollment :
14 Patients enrolled
Trial Details
Trial ID
NCT02288845
Start Date
October 1 2014
End Date
September 1 2015
Last Update
March 10 2017
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Johns Hopkins Medical Institutions
Baltimore, Maryland, United States, 21287